RxDoctor Payments DataLook up a doctor →

Gaurav Verma, MD

Nephrology · Terre Haute, INNPI 1730201096

Payments from drug & device makers

$149,392in general payments, 2019–2025

Across 453 payments — averaging $329.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$84K
  • Fresenius USA Marketing, Inc.$30K
  • AstraZeneca$17K
  • Akebia Therapeutics Inc$9K
  • Travere Therapeutics, Inc.$5K
  • Amgen$732
  • plus $3K from 25 others

What the payments were for

  • Consulting fees$8,8637%
  • Speaking & faculty fees$97,90279%
  • Travel & lodging$6,2095%
  • Food & beverage$11,2309%
  • Education$4500%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$149,392 in reported general payments places this provider in the 90th percentile of 238 nephrology providers in Indiana.

See all nephrology providers in Indiana

Medicare billing

Part B allowed, 2024
$664,420
Medicare patients
1,371
Services billed
7,708

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tolvaptan85$516,655
FarxigaDapagliflozin Propanediol538$436,296
KerendiaFinerenone266$232,901
VelphoroSucroferric Oxyhydroxide49$154,727
FilspariSparsentan12$136,610
XphozahTenapanor Hcl41$123,733
GemtesaVibegron135$98,559
JardianceEmpagliflozin94$59,485
VeltassaPatiromer Calcium Sorbitex52$57,734
LokelmaSodium Zirconium Cyclosilicate80$41,808
AuryxiaFerric Citrate25$40,836
MyrbetriqMirabegron61$33,361
Potassium Chloride504$25,136
EliquisApixaban25$20,213
Cinacalcet Hcl67$18,729

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$17,087$478,104618 claims
BayerKerendia$83,732$232,901266 claims
Fresenius USA Marketing, Inc.Velphoro$30,214$154,72749 claims
Travere Therapeutics, Inc.Filspari$4,935$136,61012 claims
Sumitomo Pharma America, Inc.Gemtesa$128$98,559135 claims
Boehringer IngelheimJardiance$161$59,48594 claims
Akebia Therapeutics IncAuryxia$9,262$40,83625 claims
Astellas Pharma US IncMyrbetriq$20$33,36161 claims
Daiichi Sankyo Inc.Benicar$11$3,92411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 238 nephrology providers in Indiana.

Other nephrology in Terre Haute

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →